PD-1/PD-L1 blockade, as a monotherapy or in combination with IR and epigenetic targeting, has shown great promise as a novel emerging cancer treatment and is currently being tested clinically for several other solid and hematopoietic cancers (116–119). This evidence concerns the gene PDCD1 and cancer.